CEPPPIA Pilot. Experimental Center of Participative and Individualized Predictive Prevention in Auvergne

NCT03378895 | Completed

• 2 other identifiers: CHU-3582017-A00666-47
• Study Type: interventional
• Target: 251
• Locations: 1 country
• Sites: 1

Brief Summary

The state of health in France appears to be good with regard to major indicators such as life expectancy at birth. However, France is characterized by a high standardized rate of premature mortality (deaths occurring before the age of 65) in comparison with other European countries, with geographical disparities. Between 2006 and 2010, the standardized rate of premature mortality was higher in Auvergne than the national average. Chronic diseases such as cardiovascular diseases, cancers and / or metabolic diseases (including diabetes and obesity) are the main causes of these premature deaths. These diseases have several causes: they depend on the genetic heritage, the way of life and the environment. Family history is a known risk factor for these chronic diseases. Eating habits, insufficient physical activity or physical inactivity, excessive drinking and smoking which promote the occurrence of these chronic diseases are the main risk factors that we can modify. Preventive measures are known and are regularly the subject of public health plans and awareness campaigns targeting lifestyles modification of the populations. These prevention campaigns affect entire population, while the risk factors for chronic diseases are different from one to another, this encourages personalization of preventive measures. The CEPPPIA pilot study falls within this framework and aims to evaluate the feasibility of setting up an individualized prevention program on the modification of health behaviors among people aged 35 to 55, who has a moderate risk of developing chronic diseases and residing in Auvergne territory.

Conditions

Chronic Disease; Cardiovascular Diseases; Cancers; Diabetes Mellitus; Obesity

Outcome Measures

Primary Outcomes (1)

• Individualized Prevention Program participation rate

  Number of volunteers who accepted to participate in the interventional phase / number of volunteers who can be included in the study Assess the feasibility of implementing an Individualized Prevention Program on the modification of health behaviors among people aged 35 to 55 years with a risk of developing chronic diseases (cardiovascular diseases, metabolic diseases and / or cancers) and residing in the territory of Auvergne by measuring partipation rate and satisfaction

  at day 1

Secondary Outcomes (2)

• Variation of the risk score in at least one of the three behavioral domains

  at day 1

• Variation of the risk score in at least one of the three behavioral domains; The risk score will be calculated from the results reported on a self-administered questionnaire

  at 3 month

Study Arms (1)

adults aged 35 to 55 years

EXPERIMENTAL

Behavioral: online questionnaire

Interventions

online questionnaire BEHAVIORAL

Risk assessment identified by online questionnaire

adults aged 35 to 55 years

Eligibility Criteria

• Age: 35 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Men or women aged 35 to 55 years
• Subjects identified as moderate risk (group G1) following the assessment of the level of risk
• Covered by the Social Security
• Judged able to understand the aims of the study and ready to accept the constraints

You may not qualify if:

• Age \<35 years or\> 55 years
• Person who has not completed and validated the FSI (online health questionnaire)
• Person belonging to group G1 but with a moderate pathological risk (P1) and no identifiable risk in the behavioral field (C0)
• Pregnant or lactating women
• Persons benefiting from a legal protection measure
• Persons refusing to sign information and consent form
• Person deprived of his liberty by judicial or administrative decision
• Medical or surgical history, judged by the investigator to be incompatible with the study
• Suspicion of psychiatric disorders judged by the investigator to be incompatible with the study

Sponsors & Collaborators

• University Hospital, Clermont-Ferrand: lead
• European Regional Development Fund: collaborator
• Conseil Régional Auvergne-Rhône-Alpes, Clermont-Ferrand, France.: collaborator
• Agence Régionale de Santé Rhône-Alpes: collaborator
• Ligue Contre le Cancer, Puy de Dôme, Allier et Cantal: collaborator
• GIE Auvergne Thermale: collaborator
• Centre Jean Perrin: collaborator
• UFR Médecine: collaborator
• UFR STAPS: collaborator
• Laboratoire d'Informatique, de Modélisation et d'Optimisation des Systèmes (LIMOS): collaborator
• Centre de Recherche en Nutrition Humaine d'Auvergne: collaborator

Study Sites (1)

CHU Clermont-Ferrand

Clermont-Ferrand, 63003, France

Location

MeSH Terms

Conditions

Chronic Disease; Cardiovascular Diseases; Neoplasms; Diabetes Mellitus; Obesity

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Overweight; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms

Study Officials

• Ruddy RICHARD

  University Hospital, Clermont-Ferrand

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Masking Details: No masking
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 17, 2017
• First Posted: December 20, 2017
• Study Start: December 1, 2017
• Primary Completion: September 28, 2018
• Study Completion: September 28, 2018
• Last Updated: January 25, 2019

Record last verified: 2019-01

Locations

FR (1)